PH-0053 NBTXR3 activated by SBRT combined with nivolumab or pembrolizumab in advanced cancers: phase I trial. (August 2021) - Vivar, O.; Shen, C.; Frakes, J.; Niu, J.; Rosenberg, A.; Weiss, J.; Caudell, J.; Jameson, K.; Said, P.; Seiwert, T.